Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Depreciation & Amortization (CF) (2016 - 2025)

Standard Biotools (LAB) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 58.89% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.3 million through Dec 2025, down 25.99% year-over-year, with the annual reading at $9.3 million for FY2025, 25.99% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $1.3 million at Standard Biotools, down from $1.5 million in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $3.3 million in Q1 2025, with the low at $802000.0 in Q3 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $1.8 million, with a median of $1.3 million recorded in 2025.
  • The sharpest move saw Depreciation & Amortization (CF) plummeted 70.77% in 2022, then soared 280.15% in 2024.
  • Over 5 years, Depreciation & Amortization (CF) stood at $2.7 million in 2021, then tumbled by 70.15% to $819000.0 in 2022, then skyrocketed by 35.04% to $1.1 million in 2023, then skyrocketed by 183.91% to $3.1 million in 2024, then tumbled by 58.89% to $1.3 million in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $1.3 million, $1.5 million, and $3.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.